NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

  • April 2018 •
  • 196 pages •
  • Report ID: 5391523 •
  • Format: PDF
Mantle cell lymphoma (MCL) is a rare form of B-cell non-Hodgkin’s lymphoma (NHL), accounting for 3–6% of new NHL cases. The term MCL derives from the growth pattern of the lymphoma, with tumor cells originating in the mantle zone of the lymph node. The clinical behavior of MCL is usually aggressive, and the clinical presentation frequently includes extranodal involvement of the bone marrow and gut. The disease often initially responds to treatment, but disease relapse inevitably occurs within 1–2 years. The prognosis of patients with MCL is the poorest among B-cell lymphoma patients, with median overall survival of 5–7 years.
 
Recent events and opinion
 
Costly therapies will drive the growth of the mantle cell lymphoma market during 2016–25, despite multiple generic/biosimilar entries. 
Imbruvica has achieved the highest response rates among the new targeted approaches in refractory or early relapse cases, leading to its usage in previously treated patients. 
Incident cases of the three major subtypes of NHL will increase by at least a quarter over the forecast period. 
Rituxan-based therapies remain the standard of care for the treatment of mantle cell lymphoma. 
CD antigens are the main targets in the pipeline for mantle cell lymphoma.